Stocktoria
Universe Pharmaceuticals INC UPC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-03-23
Universe Pharmaceuticals INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 35.3% | 26.4% | 31.9% | 54.5% | 52.8% |
| Operating margin | -16.3% | -34.8% | -12.3% | -17.5% | 28.3% |
| Net margin | -20.6% | -37.9% | -20.4% | -19.7% | 23.6% |
| FCF margin | -29.8% | -42.2% | 3.3% | -3.5% | -5.2% |
| Return on assets | -5.3% | -12.8% | -15772.6% | -13.3% | 16.1% |
| Return on equity | -6.5% | -19.2% | -23.5% | -0.0% | 24.1% |
| Current ratio | 4.07 | 2.54 | 1.84 | 3.17 | 4.50 |
| Revenue growth | -22.4% | -28.7% | 80383.8% | -16.3% | 56.3% |
Source: SEC EDGAR filings · CIK 0001809616 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.